European equities traded in the US as American depositary receipts kicked off the week lower late Monday morning, falling 0.70% to 1,803.50 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company argenx (ARGX), which climbed 8.1% and 1.9% respectively. They were followed by petroleum refiner Equinor (EQNR) and biopharmaceutical company Grifols (GRFS), which advanced 1.8% and 1.5% respectively.
The decliners from continental Europe were led by pharmaceutical company Sanofi (SNY) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which dropped 5.5% and 4.2% respectively. They were followed by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which lost 3.3% and 1% respectively.
The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and biotech firm Autolus Therapeutics (AUTL), which rose 9.2% and 2.8% respectively. They were followed by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Amarin (AMRN), which were up 2.3% and 2.2% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and cruise line operator Carnival (CUK), which fell 2.2% and 1.6% respectively. They were followed by pharmaceutical company GSK (GSK) and biotech firm Trinity Biotech (TRIB), which were down 1.2% and 0.4% respectively.
Comments